Nontuberculous Mycobacterial Infection Market Exhibits a Revenue CAGR of 5.4 percent and Expected to Reach US 19.9 Billion by 2031 Growth Plus Reports

PRTKDelisted Stock  USD 2.18  0.00  0.00%   
About 56% of Paratek Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Paratek Pharmaceuticals suggests that many traders are alarmed regarding Paratek Pharmaceuticals' prospects. Paratek Pharmaceuticals' investing sentiment shows overall attitude of investors towards Paratek Pharmaceuticals.
  
Newark, New Castle, USA, April 24, 2023 -- As per the report by Growth Plus Reports, the global nontuberculous mycobacterial infection market size is valued at US 12.4 billion in 2022 and is expected to reach US 19.9 billion in 2031, at a CAGR of 5.4 percent during the forecast period, 2023-2031 The global nontuberculous mycobacterial infection market was valued and expected to rise during the forecast period with a significant rise in revenue share. The nontuberculous mycobacteria a

Read at finance.yahoo.com
Yahoo News
  

Paratek Pharmaceuticals Fundamental Analysis

We analyze Paratek Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Paratek Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Paratek Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Paratek Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Paratek Pharmaceuticals Related Equities

LYRALyra Therapeutics   5.00   
0%
63.0%
LPTXLeap Therapeutics   4.43   
0%
56.0%
ADAPAdaptimmune Therapeutics   3.23   
0%
40.0%
CRVSCorvus Pharmaceuticals   1.12   
0%
14.0%
JSPRJasper Therapeutics   0.40   
5.0%
0%
IMMPImmutep   2.75   
34.0%
0%
AFMDAffimed NV   2.93   
37.0%
0%
EQEquillium   4.11   
52.0%
0%
APTOAptose Biosciences   5.26   
66.0%
0%
HOOKHookipa Pharma   7.88   
100.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device